Evaluation of VX 445/TEZ/IVA in Cystic Fibrosis Subjects 6 Through 11 Years of Age

Completed · Phase 3

Conditions studied: Cystic Fibrosis

In brief

This study will evaluate the pharmacokinetics (PK), safety, tolerability, efficacy, and pharmacodynamic effect of VX-445, tezacaftor (TEZ), and ivacaftor (IVA) when dosed in triple combination (TC) in Cystic Fibrosis (CF) subjects 6 through 11 years of age with F/F and F/MF genotypes.

Key facts

Study ID
NCT03691779
Run by
Vertex Pharmaceuticals Incorporated
People needed
71
Starts
2018-10-02
Expected to finish
2020-08-07
Last updated by the study team
2021-10-22

Who can join

Age: 6 and older, up to 11. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.